Innovative A&E doctor's device poised to revolutionize hospital nebulizers

COPD patients require two critical treatments during acute hospital admissions: fixed-rate oxygen and nebulized bronchodilator drugs. Currently, these treatments are mutually exclusive, necessitating repeated rotations that result in high demand on nursing staff, increased usage of disposable equipment, and significant expenses for high-dependency patient care. The frequent rotations often lead to patient deterioration due to the intermittent withdrawal of fixed-rate oxygen during nebulization.

The Orlov nebulizer chamber offers a revolutionary solution by delivering fixed-rate oxygen simultaneously with bronchodilator drugs. Designed for compatibility with existing hospital equipment, it requires only 1 to 2 minutes of staff training. This innovative approach is anticipated to reduce the overall cost of emergency patient care and lighten nursing staff workloads.

“The reaction that I keep getting from healthcare colleagues is, ‘Why doesn’t this device already exist?’ In retrospect, it seems so obvious,” Dr. Bullock remarked upon announcing the patent application.

Pending regulatory approval, the Orlov device is expected to be integrated into future national guidelines for oxygen use in adult healthcare and emergency settings. There is a strong belief that it could become a standard practice across the UK and eventually worldwide.

CN Respiratory Solutions Ltd has been established to commercialize the Orlov device. The company is currently exploring investment opportunities, out-licensing, and development options to determine the best path forward. For more information, visit www.cnresp.co.uk.